Qual é o preço para Sorrento Therapeutics, Inc. (0L85)

O preço para Sorrento Therapeutics, Inc. (0L85) é $0.0033

Qual é a capitalização de mercado para Sorrento Therapeutics, Inc. (0L85)

A capitalização de mercado para Sorrento Therapeutics, Inc. (0L85) é $1.79M

Sorrento Therapeutics, Inc. (0L85) Desdobramentos de Ações

Sorrento Therapeutics, Inc. is a biopharmaceutical firm, active in both clinical development and commercialization, dedicated to creating treatments across a broad spectrum of illnesses, including cancer, autoimmune conditions, inflammatory disorders, viral infections, and neurodegenerative diseases. The company conducts its operations through two distinct divisions: Sorrento Therapeutics and Scilex. For cancer treatment, Sorrento employs its unique G-MAB antibody library alongside sophisticated targeted delivery methods. These include chimeric and dimeric antigen receptor T-cell (CAR-T) therapies, antibody-drug conjugates, and bispecific antibody strategies. Additionally, its Sofusa drug delivery system enables the direct administration of biologics into the lymphatic system. Sorrento's pipeline features several clinical-stage programs. These encompass an anti-CD38 CAR-T therapy targeting multiple myeloma, amyloidosis, and graft-versus-host disease. The company is also advancing resiniferatoxin, a non-opioid TRPV1 agonist neurotoxin, for managing pain associated with late-stage cancer and osteoarthritis of the knee. Furthermore, ZTlido, a lidocaine delivery system, addresses postherpetic neuralgia. In the realm of pain management, SEMDEXA, an injectable viscous gel, is undergoing Phase III trials for sciatica (a form of lower back pain); SP-103, an experimental non-aqueous lidocaine topical system, is being developed for chronic low back pain; and SP-104 is a novel, low-dose, delayed-release naltrexone hydrochloride formulation for fibromyalgia. The company maintains several strategic collaborations, including a partnership with SmartPharm Therapeutics Inc. for a gene-encoded antibody vaccine against COVID-19, and with Celularity, Inc. for a Phase I/II clinical trial involving up to 94 COVID-19 patients. Additionally, Sorrento works with Mount Sinai Health System on COVI-SHIELD, an antibody treatment for SARS-CoV-2 infection, and with Mayo Clinic on a Phase Ib pilot study utilizing Sofusa technology for Ipilimumab delivery in melanoma patients. Established in 2006, Sorrento Therapeutics operates from its headquarters in San Diego, California.

Ano	Desdobramento	Multiplicador	Multiplicador cumulativo
Não há dados suficientes para as datas fornecidas.

Ano

Desdobramento

Multiplicador

Multiplicador cumulativo

Não há dados suficientes para as datas fornecidas.

Empresa	Multiplicador cumulativo	País
Royalty Pharma plc RPRX.US	-	US
Swedish Orphan Biovitrum AB SOBI.ST	-	SE
Ipsen S.A. IPN.PA	-	FR
Recordati Industria Chimica e Farmaceutica S.p.A. REC.MI	-	IT
Corcept Therapeutics Incorporated CORT.US	-	US

Empresa

Número de desdobramentos de ações

Multiplicador cumulativo

País